A Phase 3 interventional study of Daridorexant 25 mg and Daridorexant 50 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 81 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 5th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
University Hospital, Montpellier · Sites in France
Ages 60–85
Sterling McPherson · Sites in United States
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
Institut d'Investigació Biomèdica de Bellvitge · Sites in Spain
Ages 18–99
By country, each count listing its studies:
daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2018.
This study's enrollment of 930 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd.: none open now, 1 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 3 that started in 2018, is one of 3 in phase 3, and was the 6th registered.
Idorsia Pharmaceuticals Ltd.’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2015.
3 of the studies testing daridorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07328594Legacy Health SystemImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking | 2027-03-31 |
| NCT07555743Institut d'Investigació Biomèdica de BellvitgeEfficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | 2027-04 |
| NCT05924425University Hospital, MontpellierDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease | 2027-05-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Idorsia Pharmaceuticals Ltd.’s 11 in Sleep Initiation and Maintenance Disorders:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Daridorexant 25 mg
Drug: Daridorexant 50 mg
Other: Placebo
Daridorexant will be administered as tablets, orally, once daily in the evening.
Daridorexant will be administered as tablets, orally, once daily in the evening.
Matching placebo will be administered as tablets, orally, once daily in the evening.
Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)
"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.
Time frame: From baseline to Month 1 (i.e. for up to 1 month)
Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)
"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.
Time frame: From baseline to Month 3 (i.e. for up to 3 months)
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)
"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.
Time frame: From baseline to Month 1 (i.e. for up to 1 month)
Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)
"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.
Time frame: From baseline to Month 3 (i.e. for up to 3 months)
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)
"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.
Time frame: From baseline to Month 1 (i.e. for up to 1 month)
Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)
"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.
Time frame: From baseline to Month 3 (i.e. for up to 3 months)
Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score
The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: From baseline to Month 1 (i.e. for up to 1 month)
Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score
The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: From baseline to Month 3 (i.e. for up to 3 months)
| Milestone | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Started | 310 | 310 | 310 |
| Completed | 288 | 285 | 280 |
| Not completed | 22 | 25 | 30 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event | 4 | 2 | 7 |
| Withdrew: Other reasons | 3 | 11 | 8 |
| Withdrew: Withdrawal by subject | 13 | 10 | 12 |
| Withdrew: Lost to follow-up | 1 | 2 | 3 |
"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance) | -18.40 (-22.126 to -14.674) | -28.98 (-32.668 to -25.299) | -6.20 (-9.928 to -2.475) |
"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 3 in Wake After Sleep Onset (WASO) | -22.97 (-26.955 to -18.988) | -29.41 (-33.399 to -25.427) | -11.11 (-15.131 to -7.088) |
"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset) | -28.17 (-31.509 to -24.827) | -31.20 (-34.506 to -27.896) | -19.85 (-23.177 to -16.515) |
"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS) | -30.73 (-34.037 to -27.417) | -34.80 (-38.118 to -31.490) | -23.13 (-26.464 to -19.803) |
"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST) | 34.18 (28.718 to 39.645) | 43.62 (38.173 to 49.063) | 21.56 (16.101 to 27.022) |
"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST) | 47.83 (41.333 to 54.328) | 57.67 (51.171 to 64.168) | 37.90 (31.393 to 44.404) |
The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
| Scores on a scale | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score | -2.77 (-3.316 to -2.225) | -3.77 (-4.309 to -3.224) | -2.02 (-2.566 to -1.476) |
The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
| Scores on a scale | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score | -4.78 (-5.491 to -4.067) | -5.70 (-6.405 to -4.987) | -3.79 (-4.503 to -3.080) |
Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline) | 0.49 (0.45 to 0.54) | 0.45 (0.41 to 0.49) | 0.62 (0.57 to 0.67) |
Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.
| minutes | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline) | 0.43 (0.40 to 0.48) | 0.41 (0.37 to 0.45) | 0.56 (0.51 to 0.61) |
Collected over Treatment-emergent AEs were AEs that started or worsened on or after the DB study treatment start date up to the earlier of 30 days after DB study treatment end date or the date of enrollment in the ID-078A303 extension study. The planned duration of DB treatment was 84 days ± 2 days, i.e., 12 weeks ± 2 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daridorexant 25 mg | 1/310 (0.3%) | 2/310 (0.6%) | 44/310 (14.2%) |
| Daridorexant 50 mg | 0/308 (0%) | 3/308 (1%) | 41/308 (13.3%) |
| Placebo | 0/309 (0%) | 7/309 (2.3%) | 35/309 (11.3%) |
| Event | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| SyncopeNervous system disorders | 0/310 | 1/308 | 2/309 |
| DepressionPsychiatric disorders | 0/310 | 0/308 | 2/309 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/310 | 1/308 | 0/309 |
| Haemoglobin decreasedInvestigations | 0/310 | 1/308 | 0/309 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/310 | 1/308 | 0/309 |
| Renal colicRenal and urinary disorders | 0/310 | 1/308 | 0/309 |
| Ankle fractureInjury, poisoning and procedural complications | 0/310 | 0/308 | 1/309 |
| Panic attackPsychiatric disorders | 0/310 | 0/308 | 1/309 |
| Anal abscessInfections and infestations | 0/310 | 0/308 | 1/309 |
| Herpes zosterInfections and infestations | 0/310 | 0/308 | 1/309 |
| Event | Daridorexant 25 mg | Daridorexant 50 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 28/310 | 24/308 | 24/309 |
| HeadacheNervous system disorders | 17/310 | 20/308 | 12/309 |
| Age, Categorical(Participants) | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 189 | 189 | 188 | 566 |
| >=65 years | 121 | 121 | 122 | 364 |
| Age, Continuous(years) | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.8 ± 15.3 | 55.5 ± 15.3 | 55.1 ± 15.4 | 55.4 ± 15.3 |
| Sex: Female, Male(Participants) | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 215 | 199 | 210 | 624 |
| Male | 95 | 111 | 100 | 306 |
| Race/Ethnicity, Customized(Participants) | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 51 | 44 | 51 | 146 |
| Not Hispanic or Latino | 259 | 265 | 259 | 783 |
| Unknown | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Total |
|---|---|---|---|---|
| Black or African American | 19 | 30 | 28 | 77 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 0 | 2 |
| Asian | 3 | 4 | 2 | 9 |
| White | 287 | 274 | 278 | 839 |
| Other | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Jan 2020, 19 months.
Results were first posted in Mar 2022, 2 years 2 months after primary completion. A results delay was requested in Oct 2020.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 19 months is close to that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →